Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Capecitabine in Operable Breast Cancer
NCT00148720Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2004
- Primary completion
- Sep 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in breast cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Response Rate at 12 weeks. Started Sep 2004; status: terminated.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00148720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148720.